| Previous Close | 0.6750 |
| Open | 0.6750 |
| Bid | 0.6700 x 0 |
| Ask | 0.6900 x 0 |
| Day's Range | 0.6800 - 0.6800 |
| 52 Week Range | 0.3280 - 0.7250 |
| Volume | 500 |
| Avg. Volume | 119 |
| Market Cap | 24.818M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0650 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Canntab Receives Export License Approval from Health Canada
Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.
- CNW Group
Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
* 3rd Patent Grant with Australia following the United States and Canada * Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited * Participation in Australia's Largest Cannabis Research StudyTORONTO, March 9, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No.
- Newsfile
Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.
Toronto, Ontario--(Newsfile Corp. - March 3, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE:TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2nd (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape ...
